This HTML5 document contains 76 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01000/identifier/chemspider/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01000/identifier/chebi/
n13http://bio2rdf.org/drugbank:
n4http://linked.opendata.cz/resource/drugbank/drug/DB01000/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01000/identifier/kegg-compound/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01000/identifier/pubchem-compound/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/drug/DB01000/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01000/identifier/kegg-drug/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01000/identifier/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB01000
rdf:type
n5:Drug
n5:description
A cyclohexylamido analog of penicillanic acid. [PubChem]
n5:group
approved
n5:indication
For the treatment of bacterial infections caused by susceptible organisms.
n5:manufacturer
n17:271B4E07-363D-11E5-9242-09173F13E4C5 n17:271B4E08-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB01000 n13:DB01000
dcterms:title
Cyclacillin
adms:identifier
n4:PA164743456 n7:19003 n8:46508073 n9:D01334 n12:DB01000 n14:C12766 n15:31444 n16:17941
n5:mechanismOfAction
The bactericidal activity of cyclacillin results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cyclacillin is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases.
n5:synonym
Cyclapen (2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Ciclacilline Bastcillin 6-(1-Aminocyclohexylcarboxamido)penicillanic acid Vipicil Vastcillin Cyclacillin Calthor Aminocyclohexylpenicillin Wyvital Syngacillin (1-Aminocyclohexyl)penicillin Citosarin Ciclacillum 6-(1-Aminocyclohexanecarboxamido)penicillanic acid Cyclapen-W Ultracillin Ciclacillinum Ciclacillin Ciclacilina
n5:toxicity
Symptoms of overdose include severe diarrhea, nausea and vomiting.
n5:synthesisReference
Alburn, H.E., Grant, N.H. and Fletcher, H. Ill; US.Patent 3,194,802; assigned to American Home Products Corporation. Robinson, C.A. and Nescio, J.J.; US.Patent 3,478,018; November 11,1969; assigned to American Home Products Corporation.
n19:hasConcept
n20:M0005445
n5:IUPAC-Name
n6:271B4E0D-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4E13-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4E12-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4E0F-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4E10-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4E11-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4E0B-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B4E09-363D-11E5-9242-09173F13E4C5 n6:271B4E0C-363D-11E5-9242-09173F13E4C5 n6:271B4E24-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4E0A-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B4E19-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B4E1A-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B4E14-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B4E15-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B4E17-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B4E16-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B4E18-363D-11E5-9242-09173F13E4C5
n5:absorption
Moderately absorbed.
n5:affectedOrganism
Streptococcus pneumoniae Enteric bacteria and other eubacteria Haemophilus influenzae
n5:casRegistryNumber
3485-14-1
n5:category
n5:Bioavailability
n6:271B4E1F-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4E21-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4E22-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B4E23-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B4E1E-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B4E1D-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4E20-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4E0E-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4E1B-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B4E1C-363D-11E5-9242-09173F13E4C5